In a nutshell This study wanted to see how well the medication afatinib (Giotrif) works in real-life settings, outside of clinical trials in patients with advanced non-small cell lung cancer (NSCLC). The study found that patients treated with afatinib had a good response rate and survival. Some background There are many...
Read MoreAfatinib as first-line treatment for advanced EGFR-mutant non-small cell lung cancer
